NCI Partnership IITRI is the largest commercial CRO contractor to the National Cancer Institute, offering robust preclinical safety and toxicology across rodent, non-rodent, and non-human primate studies. This proven government and industry track record makes IITRI a compelling partner for sponsors seeking IND-enabling toxicology and oncology safety data, with accessible pathways to government collaborations.

Inhalation Expertise IITRI specializes in inhalation toxicology and biodefense and infectious disease studies, enabling clients in chemicals, vaccines, antiviral programs, and biologics to access niche nonclinical testing and regulatory-ready data. This depth supports accelerated risk assessment and regulatory submissions for inhaled therapies and biodefense products.

Oncology Safety IITRI has extensive experience evaluating the efficacy and safety of cancer therapeutics and has strength in cancer biology and immunology, offering integrated safety and efficacy support to de-risk oncology assets. This combination appeals to biotech firms seeking a single partner for end-to-end preclinical oncology programs.

Agile Delivery As a mid-size CRO, IITRI emphasizes personalized attention, rapid study start dates, and flexible study design with direct involvement from PhD and DABT study directors. This agile delivery model suits growing biotech and small pharma teams needing a responsive partner and adaptable study scope.

Industry Engagement IITRI actively participates in industry conferences and maintains visible leadership, signaling ongoing business development and collaboration opportunities. Potential clients can engage through events or joint research initiatives, and IITRI’s established relationships with government and academic partners may shorten deal cycles.